600201.SS
600201.SS
CNE000000Y37
JINYU BIO-TECHNOLOGY CO LTD
Loading chart...

Company Profile

Jinyu Bio-technology Co., Ltd. engages in the research and development, production, and sale of veterinary biological products in China and internationally. The company's products focus on preventing porcine mycoplasmal pneumonia, pseudorabies, highly pathogenic avian influenza, brucellosis, and other Class I, II, and III animal diseases. It also provides pig vaccines, swine foot-and-mouth disease type O and A bivalent inactivated, porcine circovirus type 2 baculovirus vector inactivated, porcine reproductive and respiratory syndrome chimeric virus live and inactivated, and swine fever live, transmissible gastroenteritis in pigs, swine live influenza bivalent, bovine viral diarrhea/mucosal disease, infectious rhinitis two-dose inactivated, brucella gene-deleted live, brucellosis live, inactivated emphysema and gangrene, ruminant disease live, newcastle disease, infectious bursal disease trivalent inactivated, recombinant avian influenza virus trivalent inactivated, infectious bronchitis symptoms, egg drop syndrome type 4 quadrivalent inactivated infectious bronchitis, canine distemper and parvovirus bivalent live, feline panleukopenia calicivirus disease trivalent inactivated trivalent, and inactivated rabies vaccines. Further, the company manufactures and sells biological pharmaceutical preparations, and chemical reagents and auxiliaries; develops biotechnology; transfer and consulting services; advanced medical equipment and instruments; import and export of goods and technology; and provision of property management services. Additionally, it is involved in real estate activities; biochemical products; planting; hotel management services; internet information service finance; biotechnology promotion services; owner-owned house for rent; mechanical equipment processing; investment management; management, meal, technical, and medical services; and trading activities. Jinyu Bio-technology Co., Ltd. was founded in 1992 and is based in Hohhot, China.

Related stocks

9606.HK
9606.HK • China
DUALITYBIO-B
182.7 HKD
2.13B USD 1Y -42.1%
688105.SS
688105.SS • China
NANJING VAZYME BIOTECH CO LTD
26.6 CNY
2.06B USD 1Y +49.7%
301207.SZ
301207.SZ • China
HUALAN VAC
19.88 CNY
1.79B USD 1Y +14.6%
688202.SS
688202.SS • China
SHANGHAI MEDICILON INC
104 CNY
2.09B USD 1Y +53.1%
301047.SZ
301047.SZ • China
SINO BIOLOGICAL
147.12 CNY
2.68B USD 1Y +99.2%
688520.SS
688520.SS • China
SINOCELLTECH GROUP LTD
36.22 CNY
2.55B USD 1Y -35.8%
2595.HK
2595.HK • China
GENFLEET-B
28.6 HKD
1.4B USD 1Y -21%
1877.HK
1877.HK • China
JUNSHI BIO
17.65 HKD
2.31B USD 1Y -40.6%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
38.2% p.a.
Max Drawdown (5Y)
-67.1%
Sharpe Ratio (5Y)
-0.21
Beta Factor
0.67
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 91.1 (Elevated multiple compression risk)
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (38.2% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -81.6% in the extended horizon.
ende